Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy [0.03%]
一线奥希替尼单药治疗晚期非小细胞肺癌患者真实世界预后及后续治疗模式的一项多中心研究（纳入突变亚型为少见EGFR突变）
Jorge J Nieva,Xuejun Wang,Deborah Doroshow et al.
Jorge J Nieva et al.
Introduction: Osimertinib is recommended, alongside afatinib, as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) with atypical mutations in the epidermal growth factor receptor gene (EGF...
Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review [0.03%]
HER2阳性早期乳腺癌患者疾病复发的风险因素及其治疗意义：叙述性综述
Marina E Cazzaniga,Luis Costa,Gilles Freyer et al.
Marina E Cazzaniga et al.
Human epidermal growth factor receptor 2 (HER2) overexpression or amplification of the human ERBB2 oncogene occurs in approximately one-fifth of breast cancers and, of these, two-thirds are hormone receptor (HR)-positive (HR+). The introduc...
Evaluation of Event-Free Survival as a Surrogate Endpoint for Overall Survival in Muscle-Invasive Bladder Cancer Following Neoadjuvant Treatment: A Systematic Review and Meta-Analysis [0.03%]
新辅助治疗后肌层浸润性膀胱癌患者无事件生存期作为总生存期替代终点的系统评价和 meta 分析
Cora N Sternberg,Patrick Squires,Yan Song et al.
Cora N Sternberg et al.
Introduction: Event-free survival (EFS), a common endpoint in neoadjuvant/perioperative oncology trials, allows for accelerated treatment evaluation while awaiting results of overall survival (OS). However, the surrogacy ...
A Retrospective Observational Study of Extended Adjuvant Neratinib for HER2-Positive Early-Stage Breast Cancer in a European Early Access Program [0.03%]
欧洲早期通道项目中HER2阳性早期乳腺癌 extended adjuvant neratinib治疗的回顾性观察研究
Marija Križić,Tajana Silovski,Griet Hoste et al.
Marija Križić et al.
Introduction: Neratinib is approved in Europe as extended adjuvant therapy in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (EBC) who com...
Real-World Epidemiology, Clinical Characteristics and Outcomes of Women with Germline BRCA Mutation and Early Breast Cancer in China [0.03%]
中国女性早发乳腺癌携带BRCA1/2基因 germline突变的流行病学、临床特征及预后研究
Zhen Hu,Qianqian Yu,Liqin Chen et al.
Zhen Hu et al.
Introduction: The poly(ADP-ribose) polymerase inhibitor olaparib was recently approved in China for adjuvant treatment of certain patients with high-risk, human epidermal growth factor (HER2)-negative early breast cancer ...
Systematic Review and Meta-Analysis of the Management of Relapsed Germ Cell Tumours Following Cisplatin-Based Chemotherapy [0.03%]
卡铂为基础的化疗后继发复发性生殖细胞肿瘤的治疗系统的复习和荟萃分析
Nasreen Abdul Aziz,Didjier Danger Masangwi,Pinky Kotecha et al.
Nasreen Abdul Aziz et al.
Introduction: Salvage treatment options after cisplatin-based chemotherapy for germ cell tumours (GCT) are either conventional-dose chemotherapy (CDCT) or high-dose chemotherapy (HDCT). However, the optimal sequencing of ...
Patient and Physician Perspectives on Multiple Myeloma Data Presented at ASCO and EHA 2025: A Podcast [0.03%]
2025年ASCO和EHA会议公布的多发性骨髓瘤数据的患者和医师视角播客
Jenny Ahlstrom,Luciano J Costa
Jenny Ahlstrom
In this plain language podcast, highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 are discussed, supplemented with additional reflections from the European Hematology Association (EHA) 2025 Congress. These...
A Decade of Treating ALK-Rearranged Non-Small Cell Lung Cancer in a Lower Middle-Income Country: Changing Patterns and Improving Survival [0.03%]
中低收入国家治疗ALK重排非小细胞肺癌十年：不断变化的模式和改善的生存率
Ullas Batra,Mansi Sharma,Irfan Ahmad et al.
Ullas Batra et al.
Introduction: Data regarding the comparative efficacy of various generations of tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC) in lower middle-income countries (LMICs) is scarce. ...
Overlapping Extremes: An Analysis of Avelumab Maintenance and Pembrolizumab in Advanced Urothelial Carcinoma [0.03%]
重叠的极端值：阿维鲁单抗维持治疗和派姆单抗治疗晚期尿路上皮癌的分析
Martina Catalano,Irene de Gennaro Aquino,Ismaela Anna Vascotto et al.
Martina Catalano et al.
Introduction: Avelumab and pembrolizumab are approved immune checkpoint inhibitors (ICIs) for advanced urothelial carcinoma (UC) that are used as maintenance and salvage therapies, respectively. The aim of this study was ...
The Management of ER-Low, HER2-Negative Breast Cancer in the United Kingdom: A Survey of Current Clinical Practice [0.03%]
英国对ER低表达、HER2阴性乳腺癌管理的调查：当前临床实践摘要
Ka Chai Sit,Alison M Berner,Conor McCahill et al.
Ka Chai Sit et al.
Introduction: The optimal management of oestrogen receptor (ER)-low HER2-negative breast cancer (BC) is unclear. We surveyed current approaches of UK clinicians in ER-low BC, and also present outcomes of ER-low early BC a...